Stable Angina Treatments

Find Stable Angina Treatments

Treatment Overview

Stable angina is a common symptom of underlying coronary artery disease, often experienced as chest pain, tightness, or discomfort that occurs predictably during physical exertion or stress. While the symptoms are temporary and typically resolve with rest or medication, living with the anticipation of pain can cause significant anxiety and limit everyday activities. Understanding that this pain is a signal that the heart muscle is temporarily starved of oxygen is the first step toward effective management.

Treatment for stable angina is crucial for two reasons: first, to relieve the symptoms so patients can maintain an active lifestyle, and second, and most importantly, to manage the underlying disease. By controlling the progression of plaque buildup (atherosclerosis) and reducing the risk of blood clots, medications directly lower the chance of suffering a heart attack or stroke. Treatment is always tailored to the individual, balancing the need for symptom relief with the management of co-existing conditions like high blood pressure or diabetes (American Heart Association, 2024).

Overview of treatment options for Stable Angina

The comprehensive management of stable angina involves a two-pronged medication strategy: acute relief and long-term risk reduction.

Medications are the cornerstone of care, but they are supported by aggressive lifestyle modifications, including dietary changes, regular exercise, and absolute smoking cessation. The overall goals are to reduce the heart’s workload and stop the progression of plaque that causes the blockages. While surgical procedures (like stenting or bypass surgery) may be necessary for very severe blockages, most patients rely on medication to stabilize their condition, often for a lifetime.

Medications used for Stable Angina

Medication therapy for stable angina includes several drug classes, each serving a distinct purpose in improving symptoms and lowering the risk of a major cardiac event.

For immediate relief of an ongoing attack, nitrates (nitroglycerin) are essential. They are fast-acting, rescue medications that relieve pain within minutes.

For long-term daily management, multiple drug classes are used:

  • Antiplatelet Agents: Low-dose aspirin is standard for nearly all patients. It reduces the stickiness of platelets in the blood, preventing the formation of clots that can block an artery and cause a heart attack.
  • Beta-Blockers: Medications like metoprolol or atenolol are primary choices to reduce the heart’s workload and oxygen demand. They decrease heart rate and blood pressure, making the heart more resilient during exertion.
  • Cholesterol-Lowering Drugs: Statins (e.g., atorvastatin, rosuvastatin) are used to lower LDL (“bad”) cholesterol, stabilize existing plaque, and slow the disease’s progression. Studies show that aggressive statin and antiplatelet therapy stabilizes plaques and significantly reduces the risk of future heart attacks.
  • Additional Antianginals: If symptoms persist, calcium channel blockers (e.g., amlodipine, diltiazem) or newer drugs like ranolazine may be added to further reduce the frequency of chest pain episodes.

How these medications work

These medications target the fundamental problems in stable angina: reduced blood flow and increased cardiac strain.

Nitrates work by relaxing smooth muscle in the walls of the blood vessels, causing them to widen (vasodilation). This effect increases blood flow to the heart and simultaneously lowers the pressure the heart must pump against, reducing its workload.

Beta-blockers block the effects of adrenaline and other stress hormones on the heart. This reduces the heart rate and force of contraction, which in turn decreases the amount of oxygen the heart muscle needs to perform any given activity.

Statins interfere with cholesterol production in the liver. By dramatically lowering circulating cholesterol, they help shrink fatty deposits in the artery walls and stabilize plaque surfaces, making them less likely to rupture and form a dangerous clot (National Heart, Lung, and Blood Institute, 2022).

Side effects and safety considerations

Side effects vary: Nitrates cause headache, flushing, and dizziness due to vasodilation; beta-blockers may cause fatigue, cold extremities, or sexual dysfunction; statins can cause muscle aches (report to provider).

Never abruptly stop antiplatelet agents or beta-blockers, as this risks a serious cardiac event. Warn patients: combining nitrates with PDE5 inhibitors (erectile dysfunction drugs) can cause a life-threatening blood pressure drop. Call 911 if chest pain is sudden, severe, or unrelieved by rescue nitroglycerin.

Since everyone’s experience with the condition and its treatments can vary, working closely with a qualified healthcare provider helps ensure safe and effective care.

References

  1. American Heart Association. https://www.heart.org
  2. Mayo Clinic. https://www.mayoclinic.org
  3. National Heart, Lung, and Blood Institute. https://www.nhlbi.nih.gov
  4. MedlinePlus. https://medlineplus.gov

Medications for Stable Angina

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Stable Angina.

Found 4 Approved Drugs for Stable Angina

Procardia

Generic Name
NIFEdipine

Procardia

Generic Name
NIFEdipine
Form: Tablet, Capsule
Method of administration: Oral
FDA approval date: September 06, 1989
Classification: Dihydropyridine Calcium Channel Blocker
I. Vasospastic Angina PROCARDIA XL is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. PROCARDIA XL may also be used where the clinical presentation suggests a possible vasospastic component, but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion, or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta blockers. II. Chronic Stable Angina (Classical Effort-Associated Angina) PROCARDIA XL is indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers and/or organic nitrates or who cannot tolerate those agents. In chronic stable angina (effort-associated angina), nifedipine has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients is incomplete. Controlled studies in small numbers of patients suggest concomitant use of nifedipine and beta-blocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormalities. When introducing such concomitant therapy, care must be taken to monitor blood pressure closely, since severe hypotension can occur from the combined effects of the drugs. III. Hypertension PROCARDIA XL is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including PROCARDIA XL. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. PROCARDIA XL may be used alone or in combination with other antihypertensive agents.

Verapamil

Brand Names
Trandolapril, Verapamil HCI

Verapamil

Brand Names
Trandolapril, Verapamil HCI
Form: Injection, Tablet, Capsule
Method of administration: Oral, Intravenous
FDA approval date: October 01, 1986
Classification: Calcium Channel Blocker
Trandolapril and verapamil hydrochloride extended-release tablets are indicated for the treatment of hypertension. This fixed combination drug is not indicated for the initial therapy of hypertension. In using trandolapril and verapamil hydrochloride extended-release tablets, consideration should be given to the fact that an angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that trandolapril does not have similar risk.

Diltiazem

Brand Names
Cardizem, Cartia XT, Diltiazem HCI, Matzim, Tiadylt, Tiazac

Diltiazem

Brand Names
Cardizem, Cartia XT, Diltiazem HCI, Matzim, Tiadylt, Tiazac
Form: Injection, Tablet, Capsule
Method of administration: Oral, Intravenous
FDA approval date: November 05, 1992
Classification: Calcium Channel Blocker
CARDIZEM CD is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive medications. CARDIZEM CD is indicated for the management of chronic stable angina and angina due to coronary artery spasm.

Atorvastatin

Brand Names
Amlodipine, Amlodipine Besylate, Atorvaliq, Azor, Benazepril, Benicar, Caduet, Katerzia, Lipitor, Lotensin, Lotrel, Norliqva, Norvasc, Olmesartan Medoxomil, Olmesartan Medoxomil Amlodipine, Sdamlo, Tribenzor

Atorvastatin

Brand Names
Amlodipine, Amlodipine Besylate, Atorvaliq, Azor, Benazepril, Benicar, Caduet, Katerzia, Lipitor, Lotensin, Lotrel, Norliqva, Norvasc, Olmesartan Medoxomil, Olmesartan Medoxomil Amlodipine, Sdamlo, Tribenzor
Form: Tablet, Suspension, Capsule, Solution
Method of administration: Oral
FDA approval date: June 21, 1991
Classification: HMG-CoA Reductase Inhibitor
Amlodipine and benazepril hydrochloride capsules are a combination capsule of amlodipine, a dihydropyridine calcium channel blocker (DHP CCB) and benazepril, an angiotensin-converting enzyme (ACE) inhibitor. Amlodipine and benazepril hydrochloride capsules are indicated for the treatment of hypertension in patients not adequately controlled on monotherapy with either agent.
Showing 1-4 of 4
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances